Latest Articles
Oral Wnt-blocking pill plus lenvatinib shows promise in endometrial cancer after immunotherapy fails - Bioengineer.org
Oral Wnt-blocking pill plus lenvatinib shows promise in endometrial cancer after immunotherapy fails Bioengineer.org
Published: Sept. 26, 2026, 11:18 p.m.
Oral Wnt-blocking pill plus lenvatinib shows promise in endometrial cancer after immunotherapy fails - bioengineer.org
Oral Wnt-blocking pill plus lenvatinib shows promise in endometrial cancer after immunotherapy fails bioengineer.org
Published: Sept. 26, 2026, 11:18 p.m.
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? - ESMO Daily Reporter
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? ESMO Daily Reporter
Published: June 18, 2026, 2:24 p.m.
The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years - MSN
The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years MSN
Published: June 8, 2026, 8:37 p.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN
Published: June 2, 2026, 12:41 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress
Published: June 1, 2026, 8 p.m.
Immunotherapy Addition Demonstrates Sustained Survival Benefits in - Bioengineer.org
Immunotherapy Addition Demonstrates Sustained Survival Benefits in Bioengineer.org
Published: May 29, 2026, 11:56 p.m.
Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations - CancerNetwork
Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations CancerNetwork
Published: May 25, 2026, 1:56 p.m.
Managing Progression After Immunotherapy in Endometrial Cancer - OncLive
Managing Progression After Immunotherapy in Endometrial Cancer OncLive
Published: May 5, 2026, 12:07 p.m.
High response rates in platinum-resistant ovarian cancer with immunotherapy agents - MSN
High response rates in platinum-resistant ovarian cancer with immunotherapy agents MSN
Published: April 20, 2026, 8:14 a.m.
Link copied to clipboard!